Pfizer (NYSE:PFE) Issues Earnings Results


Share on StockTwits

Pfizer (NYSE:PFE) released its quarterly earnings results on Tuesday. The biopharmaceutical company reported $0.93 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.78 by $0.15, MarketWatch Earnings reports. The firm had revenue of $14.58 billion during the quarter, compared to analyst estimates of $13.41 billion. Pfizer had a net margin of 17.85% and a return on equity of 24.88%. The company’s revenue was up 44.6% compared to the same quarter last year. During the same quarter last year, the business earned $0.80 EPS. Pfizer updated its FY 2021 guidance to 3.550-3.650 EPS and its FY21 guidance to $3.55-3.65 EPS.

PFE remained flat at $$39.83 during midday trading on Tuesday. 1,900,256 shares of the company’s stock were exchanged, compared to its average volume of 31,749,029. Pfizer has a 52-week low of $31.61 and a 52-week high of $43.08. The business’s 50-day moving average price is $37.02 and its 200-day moving average price is $36.78. The company has a market capitalization of $222.16 billion, a PE ratio of 25.61, a PEG ratio of 2.79 and a beta of 0.70. The company has a current ratio of 1.40, a quick ratio of 1.13 and a debt-to-equity ratio of 0.76.

The business also recently declared a quarterly dividend, which will be paid on Friday, June 4th. Investors of record on Friday, May 7th will be given a dividend of $0.39 per share. The ex-dividend date is Thursday, May 6th. This represents a $1.56 annualized dividend and a yield of 3.92%. Pfizer’s payout ratio is currently 52.88%.

A number of research analysts have recently issued reports on the company. Royal Bank of Canada initiated coverage on Pfizer in a research note on Wednesday, April 7th. They issued a “sector perform” rating and a $42.00 price objective on the stock. JPMorgan Chase & Co. set a $36.00 price objective on shares of Pfizer and gave the company a “neutral” rating in a research note on Wednesday, February 3rd. Morgan Stanley reduced their price target on shares of Pfizer from $40.00 to $38.00 and set an “equal weight” rating for the company in a report on Friday, January 29th. DZ Bank reissued a “buy” rating and set a $41.00 price objective on shares of Pfizer in a research report on Wednesday, February 3rd. Finally, Mizuho dropped their price target on Pfizer from $44.00 to $42.00 and set a “buy” rating on the stock in a research note on Wednesday, February 3rd. Eleven equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The company has a consensus rating of “Hold” and an average price target of $38.47.

An institutional investor recently bought a new position in Pfizer stock. OLD Mission Capital LLC purchased a new stake in shares of Pfizer Inc. (NYSE:PFE) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 7,918 shares of the biopharmaceutical company’s stock, valued at approximately $291,000. 67.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zithromax, Vfend, and Panzyga brands.

See Also: What’s a Black Swan?

Earnings History for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.